8 citations
,
January 2017 in “Dermatology online journal” Tofacitinib helped psoriasis but not alopecia universalis, needing more research.
October 2004 in “Australian Prescriber” Agalsidase alfa helps treat Fabry's disease but needs more research for long-term benefits.
February 2025 in “Skin Appendage Disorders” Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” Baricitinib is effective and safe for treating severe alopecia areata.
3 citations
,
September 2016 in “Dermatologic Therapy” Doxycycline helps prevent skin issues from erlotinib in lung cancer patients.
55 citations
,
October 2019 in “Dermatology and therapy” Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
April 2026 in “Frontiers in Medicine” Upadacitinib effectively treats psoriasis and lichen planus together.
July 2025 in “Journal of Investigative Dermatology” Ritlecitinib reduces alopecia areata symptoms by blocking JAK3/TEC signaling and T-cell activity.
7 citations
,
August 2017 in “Journal of dermatological science” Sorafenib causes skin reactions by increasing the number and activity of skin mast cells.
December 2024 in “PubMed” April 2017 in “Leukemia research” Tofacitinib helped most teenagers in the study regrow hair with mild side effects.
April 2025 in “Anais Brasileiros de Dermatologia” Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.
May 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” A potential treatment for atopic dermatitis could be to increase PADI1 expression to improve skin barrier function.
November 2024 in “EMBO Molecular Medicine” JAK inhibitors may reverse early hair loss, but prolonged inflammation can cause permanent hair loss.
68 citations
,
May 2018 in “PLOS Biology” Cyclosporine A may help treat hair loss by blocking a protein that inhibits hair growth.
November 2016 in “Therapeutic Delivery” New drugs for Alzheimer's and rheumatoid arthritis advanced, a Zika vaccine is in development, and there were business deals in anesthesia and oncology.
March 2026 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
1 citations
,
October 2023 in “Clinical, cosmetic and investigational dermatology” Tofacitinib improved hair loss and skin symptoms in a patient after secukinumab caused hair loss.
Cepharanthine could be a strong antiviral against COVID-19.
October 2014 in “Cancer research” Blocking mTORC1 reduces skin tumor growth in mice.
October 2004 in “Australian Prescriber” Lifestyle changes are more effective than medication for reducing type 2 diabetes risk.
Secukinumab treatment may cause HBV reactivation and hair discoloration.
March 2026 in “The Journal of Dermatology” Ritlecitinib is cost-effective for severe alopecia areata in Japan.
14 citations
,
November 2016 in “Annals of Internal Medicine” Tofacitinib, an arthritis drug, helped hair growth in alopecia universalis but long-term safety needs more research.
February 2018 in “The Journal of Sexual Medicine” DA-9401 protects against hair loss, improves organ function, and prevents infertility caused by finasteride.
2 citations
,
February 2018 in “InTech eBooks” TNF-alpha inhibitors can cause various immune-related skin issues.
12 citations
,
March 2016 in “Life Sciences” The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.
June 2025 in “Phytomedicine” The formula may improve hair growth and health by boosting blood flow and reducing cell stress.
14 citations
,
May 2019 in “Human gene therapy” MC-DNA vector-based gene therapy can temporarily treat CBS deficiency in mice.
Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.